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1. Introduction 
Antibodies (Abs) have been first characterized as proteins which are produced by the 
immune system and have a sole function of binding other molecules, called antigens, with 
the goal of eliciting an immune response. In this classical conception, Abs act similarly to 
enzymes in specific binding other molecules. However, in contrast to enzymes they do not 
have the ability to catalyze chemical conversions of their bound partners. For the vast 
majority of Abs, this observation is correct. However, in a 1946 consideration of enzyme 
function, Linus Pauling first hypothesized that the active center of an enzyme is closely 
juxtaposed to a “strained configuration” of its substrate (that is, targeted against the 
structure of the transition state) rather than to the native conformation of the substrate 
molecule (Pauling, 1946). This idea led Jencks in 1969 to propose that Abs generated in an 
anti-hapten immune response against chemically stable analogs of the transition-state of a 
reaction of interest could potentially display an enzymatic activity (Jencks, 1969).  
In 1985, a general method for generating catalytic monoclonal Abzs against transition state 
analogs, and a way to use those Abs to accelerate chemical reactions, was first described 
(Schochetman & Massey, 1985). One year later two groups were able to produce the first 
monoclonal Abs with catalytic properties, which were generated against hapten analogs of 
the transition states for p-nitrophenylphosphorylcholine (Pollack et al., 1986) or for 
monoaryl phosphonate esters (Tramontano et al., 1986a, 1986b). The artificial monoclonal 
anti-hapten catalytic Abs were termed abzymes (derived from antibody enzyme).  
The evolution of the technology of artificial Abzs during the last two decades has led not 
only to the rapid development of direct approaches for the generation of Abs with specified 
properties, but also to the creation of strategies to revise the targeting specificity of 
individual Abzs. Such modifications of antigen binding specificity can be achieved 
genetically in vitro, by application of the site-directed mutagenesis, or genetic selection or 
screening (using approaches such as phage display). Alternatively, modification can be 
induced directly on purified antibody, via selective chemical modification by direct 
introduction of catalytic groups into the Ab combining site. Some studies describing these 
approaches include (Keinan, 2005, and refs therein). The employment of the approaches 
have demonstrated that the substrate specificity (and/or the specific activity) of some 
artificial Abzs is comparable to or even higher than that of enzymes with the same catalytic 
activity (Barbas et al., 1997; Janda et al., 1997; Keinan, 2005, and refs therein). 
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Artificial Abzs against transition chemical states of different reactions have been studied 
intensively (Thayer et al., 1999). Mechanistic basis for the activity of such Abzs is 
becoming well understood (Janda et al., 1997; Thayer et al., 1999; Keinan, 2005, and refs 
therein). The field of artificial Abzs has been amply reviewed recently (Martin & Schultz, 
1999; Suzuki, 1994; Keinan, 2005, and refs therein), for more detailed description of the 
relevant reactions. 
During last two decades it has become clear that auto-Abs from the sera of patients with 
different autoimmune (AI) diseases can possess enzymic activities (Suzuki, 1994; Keinan, 
2005; Nevinsky et al., 2002a, 2002b, 2003, 2005, 2010a, 2010b, and refs therein). The first 
example of a natural Abz was an IgG found in bronchial asthma patients, which hydrolyzes 
intestinal vasoactive peptide (VIP) (Paul et al., 1989), the second was an IgG with DNase 
activity in SLE (Shuster, et al., 1992), and the third was an IgG with RNase activity in SLE 
(Buneva et al., 1994). Later, different natural catalytic IgG and/or IgA, IgM hydrolyzing 
oligopeptides, proteins, DNA, RNA, nucleotides, and polysaccharides were detected in the 
sera of patients with several autoimmune (AI) and viral pathologies, and Abzs with these 
and other different activities were discovered in healthy human milk (for review see 
Nevinsky et al., 2002a, 2002b, 2003, 2005, 2010a, 2010b). 
The phenomenon of catalysis by auto-Abzs is extremely interesting and potentially 
applicable in many different fields including new types of efficient catalysts, new generation 
of drugs, evaluation of the functional roles of Abzs in innate and adaptive immunity, and 
understanding of certain aspects of self-tolerance and of the destructive or positive 
responses in AI diseases. The field of monoclonal Abzs with immunotherapeutic potential 
has recently been reviewed (Wentworth et al., 1998; Tellier, 2002; Zhou et al., 2002; Nishi, 
2003; Stockwin and Holmes, 2003; Hanson et al., 2005; Gabibov et al., 2006; Planque et al., 
2008; Wójcik & Kieć-Kononowicz, 2008). Some general possibilities of present and future 
therapeutic Abs and Abzs application were discussed in (Stockwin & Holmes, 2003). Abs 
and Abzs can be used to neutralize pathogens, toxins and endogenous mediators of 
pathology. As cell-targeting reagents, Abs can be used to modulate cytoplasmic cascades or 
to tag specific cells for complement- or effector-mediated lysis. Abs can also be modified to 
deliver toxic or modulatory payloads (small molecules, radionuclides and enzymes) and 
engineered to bind multiple epitopes or even to have novel catalytic activity. The modular 
structure of Igs and the availability of Ab fragment libraries also make it possible to produce 
variable-domain therapeutics (Fab, single-chain and domain of Abs). Although exhibiting 
less favorable kinetics in vivo, these fragments are straightforward to express and easily 
penetrate tissues, making them especially useful as neutralizing or delivery agents. The 
number of approved Abzs is expected to increase in the near term, as the platform is 
adopted as a viable alternative to small molecule discovery (Stockwin & Holmes, 2003). The 
Abzs strategy can be employed for new methods of drug synthesis, as well as for in vivo 
therapies. Catalytic antibodies seem to be a promising tool for therapeutic purposes, because 
of their specificity and stereoselectivity. For instance, cocaine-hydrolyzing Abzs have been 
developed, and may provide a novel approach to the problems of drug addiction (Hanson et 
al., 2005). Possible application of Abzs for prodrug activation and their potential utility in 
clinical oncology was also discussed (Nishi, 2003). Abzs have two distinct advantages over 
canonical enzymes: first, they can be selected to perform reactions not catalyzed by 
endogenous enzymes, and second, they can be humanized to minimize their 
immunogenicity (Stockwin & Holmes, 2003). 
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2. Features of the immune status of patients with AIDS, bacterial, and 
autoimmune diseases 
HIV-1 is the etiologic agent of an extremely dangerous human disease, AIDS (Fauci et al., 
2008, and refs therein). The association of immune dysfunction in patients with HIV 
infection and AIDS and the development of AI diseases are very interesting. At this moment 
the spectrum of reported autoimmune phenomena in AIDS patients is increasing (for review 
see Zandman-Goddard & Shoenfeld, 2002). A special feature of ADs is high concentrations 
of auto-Abs (Abs to many different endogenous antigens) (Zouali, 2001; Pisetsky, 2001). The 
development of AI diseases is characterized by spontaneous generation of primary Abs to 
proteins, nucleic acids and their complexes, polysaccharides, nucleotides etc. (Earnshaw & 
Rothfield, 1985; Raptis & Menard, 1980). Later the secondary idiotypic and then 
antiidiotypic Abs to the primary ones are usually generated, etc. Immunization of animals 
with DNA or RNA and especially their complexes with proteins leads to the production of 
anti-DNA and anti-RNA Abs (Gottieb & Shwartz, 1972; Mitsuhashi et al., 1978).  
During frank loss of immunocompetence, AI diseases that are predominantly T cell subtype 
CD8 driven predominate. There is evidence for B cell stimulation and many auto-Abs are 
reported in HIV patients. HIV-dependent activation of B lymphocytes leads to the 
production of auto-Abs not only to different viral proteins including HIV reverse 
transcriptase (RT) and integrase (IN), but also to human cell components, and various 
immune complexes including anti-cardiolipin, anti-beta2 GPI, anti-DNA, anti-small nuclear 
ribonucleoproteins, anti-thyroglobulin, anti-thyroid peroxidase, anti-myosin, and anti-
erythropoietin and possibly other human cell and blood components (Fauci et al., 2008; 
Zandman-Goddard & Shoenfeld, 2002). The list of reported autoimmune diseases in 
HIV/AIDS includes SLE, anti-phospholipid syndrome, vasculitis, primary biliary cirrhosis, 
polymyosits, Graves' disease, and idiopathic thrombocytopenic purpura (Zandman-
Goddard & Shoenfeld, 2002). The presence of AI phenomena and production of auto-Abs in 
chronic bacterial and viral infections including HIV could be related to molecular mimicry 
between microbial or viral and host antigens (Zandman-Goddard & Shoenfeld, 2002; 
Hentati et al., 1994; Ternynck et al., 1991), altered self, abnormal expression of 
immunoregulatory molecules, and the anti-idiotypic network (Barzilai et al., 2008). 
Interestingly, some other viral infections similarly to ADs can also demonstrate AI reactions 
leading to the formation of Abs to various human and viral antigens. Compared with 
healthy donors, concentrations of DNA and anti-DNA Abs are higher not only in patients 
with SLE (36% of SLE patients), but also in multiple sclerosis (17-18%), primary Sjogren's 
syndrome (18%), Hashimoto’s thyroiditis (23%), myasthenia gravis (6%), rheumatoid 
arthritis (7%), autoimmune hepatitis (Shoenfeld et al., 1988, 1989), and also in 
lymphoproliferative (Kozyr et al., 1998) and some viral diseases including viral hepatitis, 
AIDS (Gololobov et al., 1994), and TBE (Garmashova et al., 2004). In the sera of patients 
with several AI diseases, RNA and anti-RNA Abs were also detected (Blanco et al., 1991; 
Sato et al., 1994; Hirokawa et al., 2002; Ikeda et al., 2003).  
AIDS, TBE, and hepatitis demonstrating strong reorganization of immune system have 
some similarities with typical AI diseases such as SLE (HT, and others) which is a systemic 
AI polyetiologic diffuse disease that is characterized by disorganization of conjunctive 
tissues with the paramount damage to skin and visceral capillaries (Hhachn, 1996). All 
known AI and viral diseases like AIDS, viral hepatitis, and TBE are characterized by 
significant disturb the immune status of the patients accompanied by humoral and cellular 
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AI reactions, with detectable tissue-specific and organ-nonspecific Abs (Bigazzi, 1983; 
Sugiama & Yamamota, 1996; Nevinsky, 2010b). At the same time, microbial and viral 
infections expose the human organism to different components from the parasite’s cells and 
viral particles, including protein, DNA, RNA, lipids, and polysaccharides. The sera of mice 
infected with different microbe’s bacterial pathogens contain a variety of Abs to the 
parasite’s antigens and to human lipids, proteins, and nuclear components, including anti-
DNA Abs (Ternynck et al., 1991; Unterkircher et al., 1993; Matsiota-Bernard et al., 1993, 1996; 
Hentati et al., 1994; Boekel et al., 1997; Wun et al., 2001). The origin of anti-DNA Abs in the 
infections remains speculative; some of them may arise inadvertently in the course of a 
normal immune response due to the induction by Abs that bear structures (mimotopes) 
mimicking DNA (Wun et al., 2001). The immunoregulatory effect of the infection seems to 
be related, at least partially, to the increase in a particular population of Abs, the 
polyreactive Abs (Matsiota-Bernard et al., 1996). It has been proposed that bacterial and viral 
infectious agents can act in some cases through the mechanism of molecular mimicry and 
stimulate development of different AI diseases. For instance, the agents responsible for 
molecular mimicry in multiple sclerosis include measles, hepatitis B, herpes simplex, 
influenza, papilloma, and Epstein-Bar viruses (Steinman, 2001). Thus, AI reactions in different 
AI, viral and bacterial infection diseases are very similar and may be strongly associated.  
3. The origin of artificial and natural abzymes  
Artificial Abzs can be obtained by immunization of animals with chemically stable analogs 
of transition states of chemical reactions (reviewed in Martin & Schultz, 1999; Nevinsky et 
al., 2000a; Tanaka, 2002; Tanaka and Barbas, 2002; Dias et al., 2002; Keinan, 2005). On the 
other hand, artificial antiidiotypic Abs can also possess catalytic activity (Barbas et al., 1997; 
Wentworth et al., 1998). Building on earlier observations on the existence of idiotypic 
determinants related to the antigen, Jerne proposed that the immune system is self-
regulated by a network of idiotype–anti-idiotype interactions (Jerne, 1974). The simplified 
model of this network may be schematically presented as follows: 
 
Antibodies 1 and 2 are termed idiotype and anti-idiotype, respectively, etc. There is 
convincing evidence that such idiotype–anti-idiotype networks are actually present in the 
body. The presence of blood serum Ab4 (in the notation shown in the scheme) has been 
confirmed in experimental animals (Jerne, 1974). 
If the active site of an enzyme plays the role of antigen triggering this anti-idiotypic chain, it 
is logical to suggest that the secondary anti-idiotypic Ab2 may possess the structure, a part 
of which represents an “internal image” or “mould” of the active site of this enzyme, and, 
consequently, these Abs may possess some properties of this enzyme. This remarkable 
property of idiotypic mimicry has been exploited to raise monoclonal antiidiotypic Abzs 
with several different catalytic activities (reviewed in Keinan, 2005; Nevinsky et al., 2005).  
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The origin of natural Abzs in different AI, viral and bacterial diseases may be complex. 
Similarly to artificial Abzs against analogs of transition states of catalytic reactions, naturally 
occurring Abzs with DNase and RNase activities may be Abs raised directly against free 
DNA and RNA or these nucleic acids acting as haptens bound to different proteins and 
resembling transition states of catalytic reactions (Nevinsky et al., 2003, 2005, 2010a, 2010b, 
and refs therein). Immunization of rabbits with pure DNA and RNA generated Abs 
interacting with DNA and possessing weak DNase and RNase activities (Krasnorutskii et 
al., 2008a, 2008b). Many SLE anti-DNA Abs are directed against histone-DNA nucleosomal 
complexes appearing as a result of internucleosomal cleavage during apoptosis (Founel & 
Muller, 2002). Apoptotic cells are the primary source of antigens and immunogens in SLE, 
and certain features in recognition, processing, and/or presentation of apoptotic auto-
antigens by antigen-presenting cells can trigger AI processes (Founel & Muller, 2002). Anti-
DNA–protein and anti-RNA–protein complexes and other antinuclear antibodies were 
found in the sera of patients with multisystem connective tissue disease (Gottieb & 
Shwartz, 1972). Therefore, we have emulated such natural complexes using complexes of 
DNA and RNA with methylated bovine serum albumin (mBSA). Immunization of rabbits 
with complex of DNA and RNA with mBSA elicited production of 10-50-fold more active 
DNase and RNase IgGs, while pIgGs from animals immunized with mBSA were 
catalytically inactive (Krasnorutskii et al., 2008a, 2008b). Immunization of healthy rabbits 
with DNase I, DNase II, and pancreatic RNase A also produced anti-idiotypic IgGs with 
intrinsic DNase and RNase activities (Krasnorutskii et al., 2008c, 2008d, 2009). Thus, DNase 
and RNase Abzs in different AI diseases may be a cocktail of Abs against complexes of 
DNA and RNA with proteins and antiidiotypic Abzs to very different DNA- and RNA-
hydrolyzing enzymes. 
Healthy humans and patients with many diseases with insignificant AI reactions usually 
lack Abzs or develop Abzs with very low catalytic activities, often on a borderline of the 
sensitivity of detection methods (Nevinsky et al., 2002a, 2002b, 2003, 2005, 2010a, 2010b, and 
refs therein). Natural Abzs hydrolyzing DNA and RNA are described from the sera of 
patients with several AI (SLE; Shuster, et al., 1992; Buneva et al., 1994; Andrievskaya et al., 
2000, 2002; Vlassov et al., 1998), Hashimoto's thyroiditis and polyarthritis (Vlasov et al., 
1998), multiple sclerosis (MS) (Baranovskii et., 1998, 2001; Nevinsky et al., 2001), asthma 
(Galvita et al., 2007), and viral and bacterial diseases: viral hepatitis (Baranovskii et al., 1997; 
Vlasov et al., 1999), tick bone encephalitis (TBE; Parkhomenko et al., 2010), AIDS (Odintsova 
et al., 2006a), and several diseases caused by different bacterial infections (Parkhomenko et 
al., 2009). It was shown, that like in the case of AI-patients, IgGs with DNase activity from 
autoimmune mice are the earliest and statistically significant markers of pathology and 
these activities are detectable at the pre-disease stage, when there are no visible markers of 
SLE pathology or significant proteinuria, and anti-DNA titres are within the typical ranges 
of these indicators for healthy mice (Dubrovskaya et al., 2003; Andryushkova et al., 2007; 
Kuznetsova et al., 2007).  
Using different approaches convincing evidence was provided that, similarly to Abzs from 
SLE and MS patients (Savel'ev et al., 2003; Ivanen et al., 2002, 2004), amylase activity is 
intrinsic to autoimmune mouse polyclonal IgGs (Andryushkova et al., 2006, 2007). It was 
shown that the relative activities of IgGs from MRL-lpr/lpr mice in the hydrolysis of DNA, 
ATP, and polysaccharides correlate very well with some visible (pink spots, baldness of the 
head and parts of the back, general health deterioration, etc.) and biochemical (proteinuria, 
Ab titers to native and denatured DNA) markers of AI pathologies during various stages of 
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mouse SLE (Andryushkova et al., 2006, 2007, 2009). Similarly to Abzs with DNase and 
RNase activities, catalytic Abs with polysaccharide-hydrolysing activity can be Abs directly 
against polysaccharides and their complexes with proteins and enzymes and second 
antiidiotypic Igs against different enzymes hydrolyzing polysaccharides (Andryushkova et 
al., 2006, 2007, 2009; Nevinsky et al., 2005, 2010a, 2010b).  
IgGs and/or IgMs and IgAs hydrolyzing different peptides and proteins were also found in 
AI and other diseases: vasoactive intestinal peptide (VIP) in asthma (Paul et al., 1989), 
thyroglobulin in HT and rheumatoid arthritis (Li et al., 1995; Kalaga et al., 1995), 
prothrombin in multiple myeloma (Thiagarajan et al., 2000), protein factor VIII in 
haemophilia A (Lacroix-Desmazes et al., 1999), and myelin basic protein (MBP) in MS 
(Polosukhina et al., 2004, 2005, 2006, 2006; Legostaeva et al., 2010). Some healthy humans 
produce Abzs with low VIP- (Paul et al., 1989), and thyroglobulin-hydrolyzing activities 
(Kalaga et al., 1995), but usually healthy volunteers and patients with many diseases with 
insignificant autoimmune reactions lack Abzs with proteolytic activity (Nevinsky et al., 
2002a, 2002b, 2003, 2005, 2010a, 2010b, and refs therein). Since immunization of AI mice 
results in a dramatically higher incidence of Abzs with a higher activity than in 
conventionally used normal mouse strains (Tawfik et al., 2002; Nishi, 2002), the formation of 
Abzs in AI and some viral diseases may be much more profuse. The question is why 
autoimmunization of AI patients and mice results in a dramatically higher incidence of 
catalytically inactive Abs and Abzs with enzyme properties as compared with healthy 
humans and animals. 
MRL-lpr/lpr mice spontaneously developing a SLE-like disorder are a very promising 
model to study the mechanisms of natural Abzs generation and their role in the 
pathogenesis of pronounced AI disturbances. A mutation in the lpr gene of these mice leads 
to a deficit in functional Fas ligand and dysregulation of apoptosis in homozygotes 
(Watanabe-Fukunada et al., 1992; Nagata & Suda, 1995). As a result, the mice develop SLE-
like phenotype, including accumulation of double-negative T cells (CD4– CD8– B220+ TCR+) 
in the peripheral lymphoid organs.  
Recently we have carried out the first analysis of possible correlations between the relative 
activities (RAs) of mouse IgGs in the hydrolysis of DNA, ATP, and polysaccharides with 
several clinical and biochemical markers of AI pathologies (proteinuria, Ab titers to native and 
denatured DNA) at various stages of mouse SLE (Andryushkova et al., 2006, 2007, 2009). An 
ever-growing number of observations suggested that AI diseases may originate from defects 
in hematopoietic stem cells (Ikehara et al., 1990). Therefore, lymphocyte proliferation and 
apoptosis at different stages of the AI disorder development in MRL-lpr/lpr mice were also 
studied. It was shown that IgGs from the sera of 2-7 month-old control non-autoimmune 
(CBAxC57BL)F1 and BALB/c mice and 2-3 months-old MRL-lpr/lpr mice (conditionally 
healthy mice) are catalytically inactive (Andryushkova et al., 2006, 2007, 2009). During 
spontaneous development of deep SLE-like pathology a specific reorganization of immune 
system of these mice leads to conditions associated with a production of IgGs hydrolyzing 
DNA, ATP, and polysaccharides with low catalytic activities (conditionally pre-diseased mice) 
(Andryushkova et al., 2006, 2007, 2009). First significant changes in differentiation and 
proliferation of mice bone marrow hematopoietic stem cells (HSC; granulocytic-
macrophagic colony-forming unit; erythroid burst-forming unit, and granulocytic-
erythroid-megacaryocytic-macrophagic colony-forming unit) in pre-diseased in comparison 
with healthy mice are most likely only temporary, since a transition from the pre-diseased to 
diseased mice is associated not only with an increase in the RAs of different Abzs and 
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proteinuria, but also with a significant additional change in the profile of HSC differentiation. 
This change seems to be the most important factor in the irreversible switching of the mouse 
immune system to an AI mode, since the changes in cell proliferation and apoptosis in 
different organs occur mainly on transition from healthy to pre-diseased mice and the 
observed differences in these indices between pre-diseased and diseased mice are 
insignificant (Andryushkova et al., 2006, 2007, 2009). Immunization of healthy young AI 
mice leads to the highest increase in urine protein, titers of anti-DNA Abs as well as DNase, 
amylase and ATPase Abz activities, occurring in parallel with a significant decrease in 
apoptosis, especially in bone marrow, thymus and spleen. However, the profile of HSC 
differentiation in immunized mice is quite different from the pre-diseased and spontaneously 
diseased mice, but comparable with that for young healthy animals. It was shown, that in 
contrast to spontaneously diseased AI mice, immunization with DNA does not remarkably 
affect bone marrow stem cells; the increased levels of anti-DNA Abs and Abzs in 
immunized mice may be mainly provided by an activation of lymphocyte differentiation 
and proliferation in different organs, first of all in the spleen, with a concomitant decrease in 
apoptosis. A significant decrease in apoptosis in the immunized mice may be an important 
factor providing the increased number of specific lymphocytes producing auto-Abs and 
Abzs, which are normally eliminated. Very high urine protein concentration and visible 
markers of SLE demonstrated by the immunized mice may be a result of kidney and spleen 
dysfunction (Andryushkova et al., 2006, 2007, 2009). Overall, in contrast to immunization of 
healthy mice an appearance of Abzs and increase in their activity is associated with changes 
in differentiation and proliferation of mice bone marrow HSC. At the onset of AI diseases 
(pre-disease condition), Abs are usually contain catalytic Abzs produced by a single clone, 
or at least a relatively narrow repertoire of Abzs with relatively low relative activities. In the 
course of chronic AI pathology development, the repertoire of Abzs constantly widens and 
Abs with significantly higher RAs can be found. In addition, the number of Abzs with high 
RAs usually increases during exacerbation of AI pathologies (Nevinsky et al., 2003, 2005, 
2010a, 2010b, and refs therein). It should be mentioned, that the detection of Abzs was shown 
to be the earliest and statistically significant indicator of development of different 
autoimmune diseases in humans (Nevinsky et al., 2003, 2005, 2010a, 2010b, and refs therein) 
and animals (Andryushkova et al., 2006, 2007, 2009). 
4. Catalytic antibodies of HIV-infected patients 
4.1 Purification of natural abzymes 
Natural Abzs from sera of patients are usually polyclonal in origin and are products of 
different immuno-competent cells (Nevinsky et al., 2000b, 2002a, 2002b, 2003, 2005, 2010a, 
2010b, and refs therein). Natural Abz purification is one of the most complicated aspects of 
their study; it was discussed in detail in review (Nevinsky et al., 2000b). 
In study Abzs from the sera of HIV-infected patients, electrophoretically and 
immunologically homogeneous AIDS Ab fraction (pIgG+pIgM+pIgA) was first purified by 
chromatography of the serum proteins on Protein A-Sepharose under conditions that 
remove non-specifically bound proteins (Odintsova et al., 2006a, 2006b; Baranova et al., 2009, 
2010). pIgMs were separated from pIgAs and pIgGs by FPLC gel filtration of the total Ab 
fraction on a Superdex 200 (Baranova et al., 2009, 2010). The homogeneity of the 150 kDa 
IgG was confirmed by SDS-PAGE with silver staining, which showed a single band under 
nonreducing conditions and two bands corresponding to the H and L chains after reduction 
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(Fig. 1). Since IgM has a very high molecular mass (~970 kDa), it cannot enter SDS-PAGE 
gels under nonreducing conditions (Fig. 1A, lane 2). Two bands corresponding to the H and 
L chains of pIgMs were evident after Ab reduction (Fig. 1B, lane 1). The absence of any 
protein bands in the gel corresponding to pIgMs under nonreducing conditions (Fig. 1A, 
lane 2) and the presence of only two bands corresponding to the heavy and light chains 
under reducing conditions (Fig. 1B, lane 1) demonstrates the absence of protein 
contaminations in the pIgM preparations. 
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Fig. 1. SDS-PAGE in a nonreducing 4–15% gradient gel followed by silver staining of control 
pIgGs (lane 1) and pIgMs (lane 2) after affinity chromatography on protein A-Sepharose and 
FPLC gel filtration on a Superdex 200 column (A). SDS-PAGE of pIgGs (lane 2) and pIgMs 
(lane 1) in a reducing 12% gel (B). 
4.2 Criteria to establish that catalytic activity is intrinsic to antibodies 
The application of rigid criteria allowed the authors of the first article concerning natural 
Abzs (Paul et al., 1989) to conclude that VIP-hydrolyzing activity is an intrinsic property of 
Abs from the sera of patients with asthma. Later several additional criteria were proposed 
(for review see Nevinsky et al., 2000a, 2002a, 2002b, 2003, 2005).  
It was shown that non-fractionated on affinity sorbents bearing immobilized DNA or 
specific protein substrates, pIgGs and pIgMs from HIV infected patients effectively 
hydrolyze DNA (Odintsova et. al., 2006a), HIV-1 RT, human casein, human serum albumin 
(HAS; Odintsova et. al., 2006b), and HIV-1 IN (Baranova et. al., 2009, 2010) but not many 
other tested proteins. We applied a set of strict criteria worked out previously (Paul et al., 
1989, Nevinsky et al., 2000a, 2002a) for an analysis of DNase and proteolytic activity as an 
intrinsic property of AIDS IgGs and/or IgMs. The most important of these are: i) 
electrophoretic homogeneity of pIgGs and pIgMs (Fig. 1); ii) the complete absorption of 
AIDS IgGs and IgMs with the DNase or proteolytic activities by Sepharose bearing 
immobilized anti-light chain of human Abs leading to a disappearance of the activity from 
the solution and recover following its elution with an acidic buffer (pH 2.6); iii) FPLC gel 
filtration of IgGs using an acidic buffer (pH 2.6) did not lead to a disappearance of the 
activity, which tracked exactly with IgGs or IgMs. The fulfilment of these criteria was 
observed for Abzs with all activities mentioned above (Odintsova et. al., 2006a, 2006b; 
Baranova et. al., 2009, 2010).  
To exclude possible artefacts due to hypothetical traces of contaminating enzymes, pIgGs 
were subjected to SDS-PAGE in a gel co-polymerized with calf thymus DNA, and their 
DNase activity was detected by incubating the gel in the standard reaction buffer (Fig. 2). 
Ethidium bromide staining of the gels after the electrophoresis and refolding of IgGs 
revealed sharp dark bands against a fluorescent background of DNA. Fig. 2B demonstrates 
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a typical example for AIDS IgGs (lane 1); there was no hydrolysis of DNA by control Abs 
from healthy donors (lane 2). Control human urine (lane 3) and bovine pancreatic DNase I 
(lane 4) also cleaved DNA, but produced bands in the position well below (33–36 kDa) the 
intact pIgGs (150 kDa). Since SDS dissociates all protein complexes, the detection of the 
DNase activity in the gel zone corresponding only to intact IgGs together with the absence 
of any other activity band or protein band (Fig. 2B), provides direct evidence that AIDS 
pIgGs hydrolyze DNA and are not contaminated by canonical DNases. In addition, after 
incubation of IgGs with DTT only light chains of AIDS IgGs demonstrated DNase activity 
(Fig. 2C). 
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Fig. 2. In situ SDS-PAGE analysis of DNase activity of AIDS intact IgGs (lane 1), healthy 
humans (lane 2) (B); human urine (lane 3) and bovine pancreatic DNase I (lane 4, B) in 
nonreducing conditions. IgGs were analyzed in reducing conditions after Abs incubation 
with DTT (C). After electrophoresis, the gel containing 3 g/ml thymus DNA (B and C) was 
incubated under special conditions for protein refolding and hydrolysis of nucleic acids; the 
nuclease activity was visualized by ethidium bromide staining of the gels (B and C). The 
longitudinal slices of the same gel were used for Coomassie R250 staining to reveal the 
positions of IgG bands (lane 2, A) and protein molecular mass markers (lane 1, A). 
AIDS IgGs and IgMs were separated by SDS-PAGE respectively under nonreducing and 
reducing conditions and their proteolytic activity was detected after the extraction of 
proteins from excised gel slices (Baranova et. al., 2009, 2010). The detection of IN-
hydrolyzing activity in the gel region corresponding only to IgG, together with the absence 
of any other bands of the activity or protein, provided direct evidence that IgG possesses IN-
hydrolyzing activity. Similar results were obtained for AIDS IgGs hydrolyzing HIV RT, 
HSA, and human casein (Odintsova et. al., 2006b). 
As mentioned above, pIgMs cannot enter the gel. The absence of IN-hydrolyzing activity 
from all gel zones corresponding to the intact pIgMs under nonreducing conditions (data 
not shown), together with hydrolysis of IN only with separated heavy and light chains of 
IgMs under reducing conditions and the absence of any other bands of the activity (Fig. 3) 
provides a direct evidence that IgM possesses IN-hydrolyzing activity.  
It was shown (Odintsova et. al., 2006b), that in contrast to known different nonspecific 
proteases hydrolyzing many proteins, AIDS pIgGs non-fractionated by affinity 
chromatography on Sepharoses bearing specific immobilized proteins efficiently hydrolyze 
only: human casein > HIV-1 RT > HSA but not many other tested proteins. Later it was 
shown that AIDS IgGs and IgMs also hydrolyze HIV-1 integrase (for example, Fig. 4) 
(Baranova et. al., 2009, 2010).  
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Fig. 3. SDS-PAGE analysis of IN-hydrolyzing activity of AIDS IgMs. After reducing SDS-
PAGE of purified AIDS IgMs the gel was incubated under special conditions for 
renaturation of Abs. The relative IN-hydrolyzing activity (RA, %) was quantified using the 
extracts of fragments (2–3-mm each) of one longitudinal slice of the gel corresponding to 3 
individual IgMs: (■), IgM1; (□), IgM2; (∆), IgM3. 
It was shown that immunogenic VIP (Paul et al., 1989), human MBP (Ponomarenko et al., 
2006; Legostaseva at al., 2010), human milk casein (Odintsova et al., 2011), stimulate 
formation of Abzs which in contrast to canonical proteases efficiently hydrolyze only 
antigen-proteins, but not many other proteins tested. To analyze the “average” proteolytic 
activity of AIDS Abzs, two mixtures of equal amounts of electrophoretically homogeneous 
pIgGs (pIgGmix) and pIgMs (pIgMmix) with different relatively high and average activities 
from the sera of seven patients were prepared. After purification of anti-IN Abs on IN-
Sepharose these Abzs hydrolyzed only IN and cannot hydrolyze other proteins including 
viral RT (Fig. 4). In addition, it was shown that AIDS pIgGs and pIgMs after their 
purification on sorbents bearing immobilized HIV RT (Fig. 4), human casein or HSA 
specifically hydrolyzed only cognate protein, but not many other proteins including HIV IN 
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Fig. 4. SDS-PAGE analysis of protein hydrolysis by AIDS IgGs and IgMs. A, HIV-1 IN was 
incubated for alone (1) or in the presence of pIgGs from two healthy donors (2 and 3) and 
pIgGs from two different AIDS patients (4 and 5), or with AIDS IgGs purified on IN-
Sepharose (6). B, AIDS IgMs purified on RT-Sepharose were incubated with different 
proteins without (odd numbers) and with Abs (even numbers): HIV-1 IN (1 and 2); p66 HIV 
RT (3 and 4); HSA (5 and 6); myelin basic protein (7 and 8). Lane 9 corresponds to mixture of 
standard protein markers with known molecular masses.  
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 (Odintsova et al., 2006b). It means that within pools of AIDs pIgGs and pIgMs only specific 
anti-IN Abzs are able to hydrolyze intact globular molecules of viral integrase (Baranoba et 
al., 2009, 2010), while specific anti-HSA, anti-casein, and anti-RT IgGs hydrolyze their 
specific target proteins (Odintsova et. al., 2006b). 
4.3 Comparison of the relative catalytic activity of Abs from different AIDS patients  
Sera of ten healthy donors, 110 HIV-infected patients (18–40-years-old; men and women) 
including 65 at the stage of pre-AIDS and 45 at the stage of generalized lymphadenopathy 
(GL) according to the classification of the Center of Disease Control and Prevention were 
used to analyze the catalytic activities of IgGs and IgMs (Odintsova et al., 2006a, 2006b; 
Baranova et al., 2009, 2010). Patients with pre-AIDS stage were characterized by a decrease in 
their body mass up to 10%, fungal, bacterial and viral lesions of skin and mucosal surfaces, 
shingles, repeating pharyngitis, sinusitis, otitis, and frequent acute respiratory infection.  
Polyclonal IgGs from 10 healthy controls were inactive in DNA hydrolysis (Odintsova et al., 
2006a). Similar results were obtained earlier for several groups of 10-20 healthy humans used 
as controls in the studies of DNase Abs from the sera of patients with AI diseases (Nevinsky 
et al., 2003, 2005, 2010a, 2010b and refs therein).The type of plasmid supercoiled (sc) DNA 
hydrolysis by AIDS pIgGs did not depend on the Ab concentration and the rate of the 
hydrolysis linearly increased with the increase in IgG concentration and time of incubation 
(Odintsova et al., 2006a). Fig. 5 illustrates a cleavage of plasmid DNA (14 g/ml) by Abs (0.3 
mg/ml) from several AIDS patients after 4 h of incubation. One can see that in this period 
some Abs cause only single breaks in one strand of supercoiled DNA (lanes 1-3), whereas 
others cause multiple breaks and as a result the formation of linear DNA (lanes 4-6). The 
most active Abs hydrolyze DNA into short and medium length ODNs (lanes 7-10). It should 
be mentioned that Fig. 5 in principle illustrates a range of possible changes of the relative 
DNase activities for patients with not only AIDS but also with different AI diseases and 
viral pathologies previously analyzed (Nevinsky et al., 2000a, 2003, 2005, 2010a, 2010b and 
refs therein). When passing from one pathology to another only the values of a relative 
percent of patients with low, middle and high DNase activities is usually changed. 
 
 
Fig. 5. DNase activities of catalytic AIDS IgGs from different patients in the cleavage of 
supercoiled (sc) and nicked (n) plasmid DNA (14 g/ml). Lanes 1–10, IgGs (0.3 mg/ml; 
incubation for 4 h) from the sera of 10 different patients; C1, scDNA incubated alone; C2 and 
C3, scDNA incubated with Ab from the sera of two healthy donors. 
The efficiency of DNA cleavage was calculated from the increase of DNA in the band of 
scDNA (10-40 % of initial DNA hydrolysis); the measured RAs (%) for IgGs were 
normalized to standard conditions (0.1 mg/ml Abs, 2 h) and a complete transition of scDNA 
to its relaxed form was taken for 100%. While four AIDS IgG preparations were completely 
inactive, the remaining 106 IgG samples (96 %) demonstrated the RAs from 5 to 100% of 
scDNA hydrolysis (Table 1). 
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On the fist step we have analyzed the RAs of proteolytic activity of AIDS pIgGs in the 
hydrolysis of many different proteins including HIV RT, HSA, and human -casein 
(Odintsova et al., 2006b). It was shown that among all proteins used, IgGs from different 
HIV-infected patients with detectable or high rate hydrolyze only HIV-1 reverse 
transcriptase (RT), human serum albumin (HSA), and human -casein. Interestingly, the 
highest rate of the hydrolysis was observed for -casein (Odintsova et al., 2006b). Therefore, 
the RA of 110 AIDS IgGs in the hydrolysis of casein was analyzed. The efficiency of casein 
cleavage was analysed by SDS-PAGE and calculated from the decrease in the band of non-
hydrolyzed casein taking into account the control reaction incubated in the absence of IgGs. 
 
Relative activity, % of  
scDNA hydrolysis  
Number of IgG preparations 
with DNase activity**  
Number of IgG preparations 
with casein-hydrolyzing 
activity*** 
0 4 (4 %)* 5 (5 %) 
5 – 20 21 (19 %) 11 (10 %) 
21 – 40 33 (30 %) 24 (21.4 %) 
41 – 60 18 (16.4 %) 25 (22.7 %) 
61 – 80 7 (6.4 %) 20 (18.2 %) 
81 – 100 17 (15.5 %) 25 (22.7 %) 
Number of preparations and 
stage of disease  
Average DNase RA Average protease RA 
Generalized 
lymphadenopathy (45)  
40.2 % ± 26.3 % 53.6 %  22.6 % 
pre-AIDS (65) 44.7 % ± 21.3 % 51.5 %  25.9 % 
*Percent of total number of patients (110) is given in parenthesis. 
**A complete transition of 14 g/ml scDNA to its relaxed form (0.1 mg/ml IgGs, 2 h) was taken for 100%. 
***A complete hydrolysis of 0.1 mg/ml human -casein (0.1 mg/ml IgGs, 2 h) was taken for 100%. 
Table 1. The relative catalytic activities of AIDS IgGs in the hydrolysis of scDNA and -
casein in the case of total group and patients with different stages of diseases development.  
Purified pIgGs from ten healthy donors were unable to catalyze casein hydrolysis, whereas 
105 of 110 IgGs (95 %) demonstrated high or detectable casein-hydrolyzing activity (Table 
1). With the development of the disease at the stage of pre-AIDS, IgGs from some patients 
demonstrated a high DNase activity (≥80 % of DNA hydrolysis) but the average RA was 
44.7 %  21.3 % (Table 1). At the stage of generalized lymphadenopathy, IgGs from 4 of 45 
patients (8.8 %) did not possess detectable DNase activity. However, the average RA value 
of DNase activity for this group of patients (40.2 %  26.3 %) was comparable with that for 
the pre-AIDS group. At the same time, the number of IgG preparations with very high 
activities (≥80 % of DNA hydrolysis) was significantly lower in the GL group. At the GL 
stage, 5 of 45 (11 %) Abs were completely inactive, while several IgGs demonstrated high 
RA in the hydrolysis of casein (up to 86.7%); the average RA for all 45 patients was 53.6 %  
22.6 % (Table 1). All 65 IgGs from patients with pre-AIDS were catalytically active, but the 
average RA (51.5 %  25.9 %) was comparable with that for IgGs from patients with GL 
(Table 1). Each group of patients corresponding to GL and pre-AIDS stage was divided into 
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two subgroups with either rapid or slow progression of the disease. According to the 
recommendations of the Center of Disease Control and Prevention, the transition time from 
GL to pre-AIDS stage (≤ 2 and > 2 years, respectively) was used as the measure of the 
disease rate of progression. The number of GL patients demonstrating a detectable 
proteolytic activity was comparable in the case of rapid (41.7 %) and slow (47.8%) 
progression, while DNase activity was observed in 41.3 % of the patients with rapid 
progression and only in 29.5% of the patients with slow progression. In the pre-AIDS group, 
the number of IgGs with DNase and proteolytic activity was slightly higher in patients with 
rapid progression (55.8 and 58.1 %, respectively) than in patients with slow (50.7 and 51.8 %) 
progression of the disease. 
On first glance, high activity of IgGs from the blood of AIDS patients in hydrolysis of β-
casein (which is not a typical component of human blood) is unexpected. However, it was 
recently shown by 2D electrophoresis that six of nine sera from AIDS patients contained Abs 
against casein, and five against human milk lactalbumin (Goldfarb, 2001). Thereby, the 
activation of β-casein synthesis in AIDS patients driven by not yet understood factor can not 
be excluded. It is interesting that mRNA corresponding to the gene encoding for β-casein is 
produced in mouse T-killer cells (also for unknown reason) (Grusby et al., 1990). In this way, 
it can not be excluded that genes, encoding for β-casein, as well as this protein itself, can 
play a special (but not yet known) role in the HIV virus life cycle, its replication, or 
development of AI reactions in AIDS patients. 
At the same time, so far Abzs hydrolyzing HSA were found only in AIDS patients. A 
possible reason of production of HSA-hydrolyzing Abs in AIDS patients is also not known. 
Later the RAs of AIDS IgGs (Baranova et al., 2009) and IgMs (Baranova et al., 2010) in the 
hydrolysis of IN were analyzed. Sera of 19 HIV-infected patients (18-40 yr old; men and 
women) including 13 at the stage of pre-AIDS and 6 at the stage of GL were used to study 
IN-hydrolyzing activity of IgGs, while 18 Ab preparations corresponding to pre-AIDS stage 
and 8 preparations to GL were used to analyze RAs of IgMs.  
pIgGs and pIgMs from ten control healthy donors were unable to catalyze IN hydrolysis. 
Interestingly, 11 of 13 IgGs from patients with pre-AIDS (84.6 %) and 6 of 6 (100 %) with GL 
demonstrated detectable of high IN-hydrolyzing activity (Baranova et al., 2009). There was 
no statistically significant difference in the IgG RAs between the two groups of patients; 
average values of IgG IN-hydrolyzing RAs were 1.99 ± 1.68 for pre-AIDS and 3.4 ± 1.31 (M 
IN/1h)/mg of Abs for GL patients. All 16 IgMs purified from patients with pre-AIDS 
(100%) and 6 of 8 IgMs (75%) from patients with GL demonstrated high or detectable IN-
hydrolyzing activity (Baranova et al., 2010). There was no statistically significant difference 
(p = 0.71) in the IgM RAs between the two groups of patients; the average values of IgM IN-
hydrolyzing RAs were 3.8 ± 2.2 M IN per hour per mg of Abs (range 0.3–7.3 M IN per 
hour per mg of Abs) for pre-AIDS and 3.3 ± 2.6 M IN per hour per mg of Abs (range 0–8.1 
M IN per hour per mg of Abs) for GL. 
Overall, in the case of Abs with DNase, casein-, and IN-hydrolyzing activity we have found 
only a negligible difference in the RAs of Abs from HIV-infected patients at the GL and pre-
AIDS stages. However, it is not surprising and agrees with the published data that a 
detection of Abzs is the earliest indicator of the development of many AI diseases in humans 
and animals (Andryushkova et al., 2006, 2007, 2009; Nevinsky et al., 2005, 2010a, 2010b, and 
refs therein). According to our data, various catalytic activities of Abzs are usually very 
easily detectable at the onset of AI diseases when the total concentrations of non-catalytic 
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Abs to specific auto-antigens have not yet increased significantly and correspond to their 
ranges for healthy donors. At the early stages of AI diseases, the repertoire of Abzs is 
usually relatively small but it greatly increases with the progress of the disease, leading to 
the generation of catalytically diverse abzymes with different activities and functions 
(Nevinsky et al., 2003, 2005, 2010a, 2010b and refs therein). In addition, AI reactions in the 
case of some viral diseases including AIDS patients are in some extent similar to AI diseases. 
At the same time, immunization of AI mice produces an unexpectedly high increase in the 
number of clones secreting various auto-Abs, including Abzs, in comparison with normal 
mice (Nishi, 2002; Tawfik et al., 2002). 
HIV-1 RT- and IN-hydrolzying pIgGs and IgMs from HIV-infected patients were the first 
examples of catalytic Abzs produced in humans against viral proteins after a viral infection 
(Odintsova et al., 2006b; Baranova et al., 2009, 2010). In addition, it was shown for the first 
time that HIV infection stimulates autoimmune reactions leading to the formation of Abzs 
that hydrolyze at least two human proteins, HSA and casein. It is known that HIV infection 
stimulates the development of many AI diseases (Zandman-Goddard et al., 2002). One can 
suppose that in some other viral and bacterial infections may induce similar processes to 
some extent. 
During many infections, the human organism is exposed to different bacterial components 
including protein, DNA, RNA, and polysaccharides (Ternynck et al., 1991; Unterkircher et 
al., 1993; Matsiota-Bernard et al., 1993, 1996; Hentati et al., 1994; Boekel et al., 1997; Wun et 
al., 2001). Because of their ability to bind a variety of exogenous antigens, including bacterial 
and viral ones, natural Abs play a major role in the primary line of defense against 
infections. Some results suggest that the synthesis of auto-Abs and Abs directed against 
bacterial antigens at least partially follow distinct pathways, but with the existing 
experimental data it is impossible to determine unambiguously whether these two Ab 
populations are produced by the same or distinct B-cell subpopulations (Matsiota-Bernard 
et al., 1993). Recently, DNase activity in the patients with diseases caused by several 
bacterial infections has been analyzed (Parkhomenko et al., 2008). The catalytic activities 
were significantly lower than in patients with different AI pathologies and increased in the 
following order: streptococcal infection (erysipelas) < urogenital chlamydiosis associated 
with arthritis (Reiter’s disease) < meningococcal meningitis < shigellosis < suppurative 
surgical infections caused by Staphylococcus aureus < suppurative surgical infections caused 
by epidermal staphylococci < urogenital ureaplasmosis associated with reactive arthritis.  
In addition, DNA-hydrolyzing IgGs was found in the sera of patients with hepatitis 
(Baranovskii et al., 1997) and tick bone encephalitis (Parkhomenko et al., 2010-11). 
Interestingly, TBE like HIV infection of humans stimulate formation of Abzs with several 
proteolytic activities (Parkhomenko T., personal communication). The RAs of IgGs in the 
hydrolysis of DNA increased in the following order: diabetes ≤ bacterial infections ≤ viral 
hepatitis < polyarthritis < Hashimoto’s thyroiditis < AIDS ≤ MS < SLE (Nevinsky et al., 2003, 
2005, 2010a, 2010b and refs therein). 
Taking these observations together, we suggest that the specific activity of polyclonal Abs 
from the sera of patients with diseases caused by bacterial infections are usually lower than 
those for typical AI diseases and most probably they can differ in their biological functions. 
It was shown that the specific reorganization of immune system during the spontaneous 
development of a profound SLE-like pathology in MRL-lpr/lpr mice is associated with 
changes in the differentiation profile and the level of proliferation of bone marrow 
hematopoietic stem cells and with production of DNase, ATPase, and amylase Abzs 
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(Andryushkova et al., 2006, 2007, 2009). Immunization of healthy mice with DNA also leads 
to production of DNase Abzs; however, it is associated only with increased lymphocyte 
proliferation and suppression of apoptosis of lymphocytes in different organs (especially 
spleen), but not with a change in differentiation of the bone marrow cells. Immune processes 
after immunization of mammals with bacterial DNA, proteins, polysaccharides during 
many infectious diseases may be considered similar to those after immunization of healthy 
mice with DNA, different proteins and enzymes. According to theoretical analysis, the 
adaptive improvement of the catalytic turnover is limited by the rate of B cell receptor signal 
transduction, as rapid release of antigen fragments from catalytic B cell receptors aborts 
clonal selection, but production of catalysts can occur at increased levels under conditions of 
rapid B cell signaling in AI disease (Paul et al., 2006). In addition, the RAs of DNase Abs 
increased with the progress of the AI pathology, while the time course of immunization 
associated with some infections is usually not so long as compared with AI diseases, which 
can have chronic character. In contrast to AI diseases, treatment and recovery of patients 
with bacterial infections usually eliminates Abzs with various activities. In addition, Abzs 
may have protective functions in patients with bacterial infections. It was shown that the 
presence of IgG endowed with serine protease-like activity in the plasma of patients with 
sepsis strongly correlates with their survival (Lacroix-Desmazes et al., 2005).  
In contrast to DNase abzymes, the polysaccharide-hydrolyzing Abs are usually present even 
in the sera of healthy humans and their activity remarkably increases in the sera of patients 
and animals with different AI diseases (Andryushkova et al., 2006; 2007) and especially with 
pathologies caused by viral infections (Buneva V.N., personal communication). Formation 
of specific Abs against DNA and other components of bacteria and some viruses during 
infections of healthy mammals suggests that the specific catalytic Abs can mostly hydrolyze 
these bacterial and viral components.  
It is possible that co-action of Abzs with proteolytic and polysaccharide-hydrolyzing 
activities can at least partially degrade bacterial cell walls and viral particles and facilitate 
the entry of Abzs into the bacterial cells and hydrolysis of bacterial DNA, proteins and other 
components. This cooperative action of abzymes with different catalytic activities may have 
a protective effect against diseases caused by bacterial and viral infections. At the same time, 
in contrast to many viral and bacterial infections, HIV-infection stimulates AI reactions. 
Therefore, at the first stage of AIDS development catalytic Abzs against different viral 
components can protect humans, similarly to the situation in bacterial and viral infections 
that do not stimulate AI reactions. Later, due to molecular mimicry between viral and host 
antigens, viral antigens can affect hematopoietic stem cells and trigger the development of 
AI processes. 
5. Extreme diversity of AIDS abzymes 
5.1 Structural diversity of AIDS abzymes 
DNase, RNase, ATPase, amylase, and protease Abzs may show very different contributions 
of variable domains of H- and L-chains to their active centers. Chromatographically 
separated light chains of IgGs from the sera of asthma patients were found to be active in 
the hydrolysis of VIP (Sun et al., 1994; 1997). The light chain of the VIP Abz was expressed 
in bacteria, purified, and found to possess an intrinsic catalytic activity (Tyutyulkova et al., 
1996). The Abz-dependent hydrolysis of DNA and RNA by isolated light chains of IgGs 
from SLE, MS, asthma, and other AI patients, as well as from MRL-lpr/lpr mice, is more 
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efficient than by intact Abs (Dubrovskaya et al., 2003; Galvita et al., 2007; Andrievskaya et 
al., 2000, 2002; Baranovskii et al., 2001; Nevinsky et al., 2005, 2010a, 2010b). A similar 
situation was observed for human milk IgGs and sIgAs with DNase and RNase activities 
(Kanyshkova et al., 1997; Nevinsky et al., 2000a). In addition, both H and L-chains of sIgAs 
had affinity to DNA-cellulose but only L-subunits hydrolyzed DNA and RNA (Nevinsky et 
al., 2000c). At the same time, it was demonstrated that the catalytic center of recombinant 
variable fragment (scFv) of DNase IgGs from AI-prone MRL-lpr/lpr mice may be located at 
the interface between the light and heavy chains and that after separation both of these 
chains are able to hydrolyze DNA (Kim et al., 2006). 
It was shown that only separated light chains of AIDS IgGs hydrolyze DNA, while heavy 
chains is catalytically inactive (Odintsova et al., 2006a). On the contrary, both light and 
heavy chains of mouse IgGs after separation were active in the ATP hydrolysis 
(Andryushkova et al., 2009). Intact rat pIgGs and their separated H- and L-chains possess 
both peroxidase and oxidoreductase catalytic activity (Nevinsky et al., 2010a). The observed 
IN-hydrolyzing activity of AIDS pIgM L- and H-chains separated by SDS-PAGE (Fig. 3) 
may have different underlying causes. First, it is possible that these pIgMs contain a mixture 
of Abzs with only light or only heavy chains being catalytically active. However, similarly to 
mouse monoclonal DNase (Kim et al., 2006), catalytic centers of AIDS IgMs hydrolyzing IN 
may be located at the interface between the light and heavy chains, with both separated 
chains capable of hydrolysis of IN.  
From the crystal structure of a catalytic Ab with esterase-like activity, it was concluded that 
the ligand p-nitrophenyl acetate interacts with amino acid residues of both light and heavy 
chains of Abzs and that both types of subunits are required for catalysis (Golinelli-
Pimpaneau et al., 1994). Taken together, it is obvious that light and heavy chains of different 
Abzs including AIDS Abs can contribute to the active sites of Abzs in different ways.  
The next question concerning the structural diversity of AIDS Abzs relates to the type of the 
proteolytic activity of their catalytic sites. Proteolytic IgGs from the sera of patients with 
asthma hydrolyzing VIP (Paul et al., 1989), Hashimoto thyroiditis and rheumatoid arthritis 
hydrolyzing thyroglobulin (Li eta l., 1995; Kalaga et al., 1995) are serine-like proteases, and 
their activity is most strongly reduced after incubation with specific serine protease 
inhibitors PMSF or AEBSF. It was shown that casein-hydrolyzing sIgAs from human milk 
(Odintsova et al., 2006; 2011) and hMBP-hydrolyzing IgGs and IgMs from the sera of 
patients with MS (Polosukhina et al., 2004, 2005, 2006) contain not only Ab subfractions with 
serine-like, but also specific subfractions with metal-dependent activity.  
We have analyzed the type of proteolytic activity of AIDS pIgGs and pIgMs in the 
hydrolysis of IN and -casein. It was shown, that in contrast to milk sIgAs (Odintsova et al., 
2006; 2011) and similarly to several other proteolytic Abzs, only specific inhibitor of serine 
protease AEBSF significantly suppress AIDS pIgG-dependent hydrolysis of -casein, while 
EDTA has no significant effect. 
We have analyzed the type of IN-hydrolyzing activity of ten AIDS pIgGs; several typical 
examples are given in Fig. 6 (Baranova et al., 2009). Leupeptin, an inhibitor of many 
different proteases, demonstrated significant inhibition of proteolytic activity of only 2 of 10 
individual AIDS IgGs (Table 2). A similar situation was observed for a specific inhibitor of 
acidic proteases, pepstatin A, which significantly inhibited IN-hydrolyzing activity of only 
two IgGs. Surprisingly, a significant inhibition of serine protease-like activity was also 
found only for 2 of 10 AIDS IgGs (Table 2). Proteolytic activity of five of ten AIDS IgGs was 
inhibited by 40-96 % after incubating the IgGs with EDTA. An incubation of IgGs with 
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iodoacetamide (a specific inhibitor of thiol proteases) usually has no remarkable effect on 
their proteolytic activity (Paul et al., 1989; Li et al., 1995; Kalaga et al., 1995; Odintsova et al., 
2006; 2011; Polosukhina et al., 2004, 2005, 2006). Surprisingly, however, IN-hydrolyzing 
activity of all 10 IgGs was inhibited by iodoacetamide by 12-98 % (Baranova et al., 2009). 
 
IgG12
IgG13
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IgG15
IgG16
IgG19
1    2   3   4   5   6    7
IN 
 
Fig. 6. SDS-PAGE analysis of a decrease in the intensity of protein band after its incubation 
with pIgGs from AIDS patients in different conditions. IN was incubated alone (1); in the 
presence of AIDS pIgGs from the sera of six different AIDS patients (IgG-12 – IgG19) and in 
the absence of other components (2) or in the presence of AEBSF (3), leupeptin (4), 
iodoacetamide (5), EDTA (6), and pepstatin A (lane 7). Arrows indicate the positions of 
molecular mass markers. 
Similar surprising situation was observed for ten AIDS pIgMs with IN-hydrolyzing activity 
(Table 2) (Baranova et al., 2010). Leupeptin, significantly inhibited the proteolytic activity of 
only two of ten individual AIDS IgMs, and very weak inhibition was observed for one more 
preparation (Table 2). A specific inhibitor of acidic proteases, pepstatin A, significantly 
inhibited the IN-hydrolyzing activity of only three pIgMs and demonstrated weak inhibition 
of two preparations (Table 2). Surprisingly, a significant inhibition of serine protease-like 
activity by AEBSF was found only for two and weak suppression of the activity for another 
of ten AIDS IgMs. Proteolytic activity of five of ten AIDS IgMs was inhibited by 33–91% 
after incubating the IgMs with 0.01 M EDTA, while this chelating reagent at 0.1 M 
concentration decreased the relative activity of six preparations by 64–98% and inhibited 
three more preparations for ~8-10% (Table 2). As for AIDS IgGs, iodoacetamide inhibited 
the IN-hydrolyzing activity of all ten of ten Abs by 30–99% (Table 2). The inhibition of AIDS 
IgGs and IgMs with EDTA was comparable with that for IgGs from patients with MS 
(Polosukhina et al., 2004, 2005, 2006).  
Iodoacetamide, a specific inhibitor of thiol proteases, usually does not significantly affect the 
activity of proteolytic Abzs (≤ 3–7% inhibition) (see above). Therefore, it was surprising that 
the IN-hydrolyzing activity of AIDS IgGs was suppressed by iodoacetamide in all 100% 
preparations by 12–98% (average value 65.7 ± 20.6%) in a stark contrast with other known 
proteolytic Abzs. A similar result was observed for AIDS IgMs; iodoacetamide suppressed 
the IN-hydrolyzing activity by 30–99% (average value 75.6 ± 21.2%) in all ten Ab 
preparations. Interestingly, there was no statistically significant difference in the inhibition 
of AIDS pIgGs and pIgMs by iodoacetamide (p = 0.2). Our findings support the idea that the 
pools of pIgGs and IgMs of AIDS patients can contain IN-hydrolyzing Abzs of four types 
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Number 
of prep. 
Inhibition, %* 
AEBSF Leupeptin Pepstatin A Iodoacetamide 0.1 M 
EDTA 
Sum of 
effects** 
IgG9 42±5 74±8 51±5 85±9 0 252 
IgG10 0 70±7 0 83±9 96±9 249 
IgG11 0 0 0 66±7 0 66 
IgG12 0 0 0 66±5 44±5 110 
IgG13 0 0 59±6 98±8 98±8 255 
IgG14 0 0 0 87±7 3±1 90 
IgG15 0 11±3 0 33±4 45±4 89 
IgG16 0 0 0 78±8 40±3 118 
IgG17 49±5 0 0 12±1.5 0 61 
IgG19 0 0 0 49±5 2±1 51 
IgM4 0 0 48 ± 5 97 ± 8 98 ± 2 243 
IgM5 0 47 ± 5 36 ± 5 36 ± 5 80 ± 7 199 
IgM7 8 ± 1 68 ± 7 0 95 ± 9 94 ± 8 265 
IgM8 0 0 7 ± 2 99 ± 8 8 ± 2 114 
IgM9 0 0 0 76 ± 6 0 76 
IgM10 0 0 0 83 ± 7 93 ± 8 176 
IgM11 0 0 0 94 ± 7 8 ± 3 102 
IgM12 0 7 ± 1 0 55 ± 5 98 ± 8 153 
IgM13 46 ± 5 0 88 ± 9 91 ± 10 64 ± 4 289 
IgM23 80 ± 8 0 5 ± 2 30± 5 10 ± 2 125 
**The decrease in the intensity of initial IN band estimated from SDS-PAGE electrophoresis data in the 
absence of inhibitor was taken for 100 %, for each preparation, a mean of 3 repeats are used. 
 **Sum of the effects of different compounds on the proteolytic activity 
(leupeptin+Pepstatin+iodoacetamide + EDTA). 
Table 2. Inhibition of proteolytic activity of individual IgGs and IgMs (from 10 AIDS patients) 
in the hydrolysis of HIV integrase by specific inhibitors of proteases of different types  
resembling thiol, serine, acidic, and metal-dependent proteases, the ratio of which may be 
individual for every HIV-infected patient. 
Interestingly, only IgM9 and three of IgGs (IgG11, IgG14, and IgG19) demonstrated 
significant inhibition by one inhibitor (iodoacetamide). At the same time other IgG and IgM 
preparations were sensitive to two or three inhibitors (Table 2). For example, IgM10 and 
IgM11 was strongly suppressed by iodoacetamide and EDTA; IgM23 was sensitive to 
AEBSF and iodoacetamide; IgM4 and IgM8 showed strong or at least some inhibition of the 
activity by three inhibitors (iodoacetamide, EDTA, and pepstatin A), while IgM12 was 
sensitive to leupeptin instead of pepstatin A (Table 2). Surprisingly, three of ten 
preparations (IgM5, IgM7, and IgM13) could be significantly inhibited by four different 
inhibitors. Of these, iodoacetamide and EDTA were common inhibitors for all three IgM 
preparations, while two other inhibitors were different: pepstatin A and leupeptin for IgM5, 
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leupeptin and AEBSF for IgM7, and pepstatin A and AEBSF for IgM13 (Table 2). Very 
comparable situations were observed for AIDS IgGs and IgMs (Table 2). 
In principle it is possible that the pools of IgGs and IgMs from AIDS patients may be 
“cocktails” of Abz molecules, with each molecule possessing only one of four alternative 
types of proteolytic activity: serine-, acidic-, thiol-, or metal-dependent. Yet the effects of 
two, three, and four inhibitors of different protease types did not always add to 100% 
inhibition. Only in three of ten IgM preparations (IgM8, IgM9, and IgM11) this sum was less 
or comparable with 100% (76–114%), while for other seven IgMs it varied from 125% to 
289% (Table 2). Three IgG preparations (IgG9, IgG10, and IgG13) demonstrated this sum 
from 249 to 255 % (Table 2). Since IgM9 had only thiol protease-like activity, and IgM8 and 
IgM11 could be significantly suppressed (94–99%) only with iodoacetamide but lost their 
activity only marginally in the presence of EDTA or pepstatin A (by 7–8 %), it is most likely 
that in these patients most of the Abz molecules possess only the thiol protease type of 
proteolytic activity (Table 2). However, since the proteolytic activity in seven of ten IgMs 
and five of ten IgGs was summarily suppressed by specific inhibitors of serine, acidic, metal-
dependent, and thiol proteases by more than 100% (110–289%, Table 2), it is possible that the 
immune system of HIV-infected patients produces anti-IN Abzs with a combined structure 
of the active center, carrying amino acid residues typical of different proteases. For example, 
we suggest that the pools of IgM4, IgM7, and IgM13 (209–289% of the summarized 
inhibition) contain IgM molecules with extremely complicated active centers containing 
structural elements of thiol and metal-dependent proteases, which may be additionally 
combined with structural elements of the active centers of acidic proteases (IgM4), serine 
proteases (IgM7), or both (IgM13). Similar suggestion is reason in the case of several AIDS 
IgGs (Table 2) (Baranova et al., 2009, 2010). 
5.2 pH optima diversity of AIDS abzymes 
Theoretically, a mammalian immune system can produce up to 106 variants of Abs against 
one antigen. An extreme diversity of RNase and DNase IgG and/or IgM Abzs from the sera 
of patients with MS and SLE and autoimmune prone MRL-lpr/lpr mice was observed 
(Baranovskii et al., 1998, 2001; Andrievskaya et al., 2000, 2002; Kuznetsova et al., 2007; 
Nevinsky et al., 2003, 2005, 2010a, 2010b). It was shown that different patients (and animals) 
may have a relatively small or an extremely large pool of polyclonal nuclease Abzs 
containing different relative amounts of light chains of - and -types, demonstrating 
maximal activity at various optimal pHs, having a different net charge, activated or not by 
different metal ions, characterized by different substrate specificities. MS IgGs of all four 
subclasses (IgG1-IgG4) were catalytically active in the hydrolysis of hMBP (Legostaeva et al., 
2010) and DNA (Parkhomenko et al., 2010).  
We have analyzed the pH dependencies of the initial rates of DNA hydrolysis by AIDS 
catalytic IgGs (Odintsova et al., 2006a). Fig. 7A demonstrates three pH dependencies of 
different types which were revealed for catalytic pIgGs from the sera of 3 different patients. 
In contrast to all human DNases having one pronounced pH optimum in hydrolysis of DNA 
(Baranovskii et al., 2004), catalytic Abs usually show high DNase activity at a wide range of 
pH values between 5.5-9.0. Nevertheless, as one can see from Fig. 7A, one of the IgG 
preparations has a pronounced optimum at pH 8.0; second at pH 7.5, while third one 
demonstrates two marked pH optima at pH 7.5 and 8.5.  
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We have analyzed the pH dependencies of the initial rates of human casein hydrolysis by 
four individual AIDS IgGs. In contrast to all human proteases having one pronounced pH 
optimum (Horl et al., 1987; Rao et al., 1998), catalytic AIDS IgGs demonstrated high specific 
casein-hydrolyzing activity within a wide range of pH values (5.0–9.0) and the pH profile 
for each IgG was unique (Fig. 7B) (Odintsova et al., 2006).  
It is well known that canonical mammalian, bacterial, and plant proteases, depending on 
their biological function, can have optimal pH values ranging from acidic (2.0) to neutral 
and alkaline (8-10) (Horl et al., 1987; Rao et al., 1998). We have measured the relative activity 
of AIDS IgGs and IgMs at pH from 3.0 to 10.5. In contrast to all human proteases, catalytic 
IgGs demonstrated high specific IN-hydrolyzing activity within a wide range of pH values 
(3.0–10). 
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Fig. 7. pH dependences of the relative DNase (A), casein-hydrolyzing (B) activity of IgGs, 
and IN-hydrolyzing activity (RA) of individual pIgGs (C) and pIgMs (D) from the sera of 
several different AIDS patients (number of Ab correspond to number of patient). The 
average error in the initial rate determination at each pH from two experiments did not 
exceed 7-10 %.  
The pH profile for each IgG and IgM was unique; each preparation demonstrated from three 
to seven brightly expressed optima at different pH from 3 to 11 (Fig. 7). Taking into account 
the effective hydrolysis of IN at pH 3.0, one cannot exclude that human immune system of 
AIDS patients could in principle produce IgGs and IgMs with a proteolytic activity similar 
to that of stomach acidic proteases. The above results clearly demonstrate that pIgGs and 
pIgMs from individual AIDS patients can consist of different sets of catalytic Ab 
subfractions demonstrating quite distinct enzymic properties in the hydrolysis of DNA, 
human casein, and integrase. 
Overall, a pool of many auto-Abs may contain very different monoclonal Abzs with various 
pH optima. It should be mentioned that the RAs of Abzs from patients with different AI and 
viral diseases are usually compared at one fixed pH, in which all samples are more or less 
active. Changing the reaction pH, one can reveal not only the major fraction of Abzs in 
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different individuals analyzed, but also other subfractions of Abs, the activity of which may 
be comparable with or less than that of the major subfraction. In addition, the number of Km 
and Vmax values, characterizing interaction of different monoclonal of polyclonal Abzs with 
their specific substrates, can significantly increase when they measured at several pH values 
(Nevinsky, 2010b). 
5.3 Affinity and relative catalytic activity diversity of AIDS abzymes 
It was shown previously, that nuclease and protease Abzs from the sera of AI patients and 
animals are very heterogeneous in their affinity for cognate substrate and can be separated 
into many fractions by chromatography on affinity resins bearing immobilized substrate 
(Baranovskii et al., 2001; Andrievskaya et al., 2002; Semenov et al., 2004; Kuznetsova et al., 
2007; Nevinsky et al., 1998, 2005, 2010a, 2010b). We have analyzed the affinity of AIDS pIgGs 
for human -casein by chromatography on casein-Sepharose (Odintsova et al., 2006b). 
Interestingly, when IgGs were eluted from casein-Sepharose by a KCl gradient (0–3 M), the 
protein (and casein-hydrolyzing activity) was distributed all over the chromatography 
profile. A similar result was obtained at AIDS IgGs chromatography on RT- and HSA-
Sepharoses (Odintsova et al., 2006b). The data indicate for extreme affinity heterogeneity of 
casein-, RT-, and HSA-hydrolyzing abzymes to cognate protein substrates (Odintsova et al., 
2006).  
We have subjected an equimolar mixture of pIgGs (and IgMs) from five AIDS patients to 
affinity chromatography on IN-Sepharose. Only 15±3 % of the total IgGs (Fig. 8A) and 173 
% of the total IgMs (Fig. 8B) were bound to IN-Sepharose (Baranova et al., 2009, 2010).  
As we have shown previously, the fraction of Abzs with different catalytic activities including 
in the serum of AI patients usually does not exceed 0.1-5 % of total Igs (Nevinsky et al., 2005, 
2010a, 2010b). Therefore, it was surprising that IN-Sepharose can bind up to 15-17 % of the total 
pIgGs and pIgMs. At the same time, IN is known as a very hydrophobic protein which can 
interact nonspecifically with different hydrophobic compounds including other proteins. 
Taking this into account we could suppose that immobilized IN binds anti-IN pIgGs and 
pIgMs in a specific manner, and interacts with some other IgGs and IgMs non-specifically.  
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Fig. 8. Affinity chromatography of the mixture of five individual AIDS pIgGs (A) and pIgMs 
(B) on IN-Sepharose: (), absorbance at 280 nm; the relative activity (RA) of IgGs and IgMs 
(5 l of dialyzed eluate, total volume of the reaction mixture 10 l) corresponding to 
complete hydrolysis of 0.3 mg/ml IN after 16 h of incubation was taken for 100%.  
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The pIgG and IgM fractions of the first peak (83-85% of protein loaded on IN-Sepharose) with 
a very low affinity for IN possess high IN-hydrolyzing activity (peak 1, Fig. 8). As it was 
shown previously non-separated on affinity resins pIgGs and IgMs from AIDS patients 
contain small subfractions hydrolyzing specifically not only HIV IN (Baranova et al., 2009, 
2010), but also HIV RT, HSA and human casein (Odintsova et al., 2006). However, the fractions 
of pIgGs and pIgMs having high affinity to IN-Sepharose and eluted from this sorbent with 
different concentrations of NaCl, MgCl2 and acidic buffer (protein peaks 2-4, activity peaks II-
V; Fig. 8) hydrolyzed only IN. Thus, IgGs and IgMs with IN-independent activities do not 
have affinity for IN-Sepharose, but some other Abs can be bound with IN non-specifically. 
The total IN-hydrolyzing activities of pIgGs and pIgMs were distributed all over the 
chromatography profiles and in the case of both Abs five peaks of IN-hydrolyzing activity (I 
– V, Fig. 8) were brightly expressed. The data obtained are indicative of extreme 
heterogeneity of IN-hydrolyzing pIgGs and pIgMs in their affinity to IN.  
When Abzs are highly heterogeneous, the dependence of V on the substrate concentration 
for non-fractionated Abs may appear inconsistent with simple Michaelis-Menten kinetics 
and may be described by a sum of several hyperbolic curves corresponding to different Ab 
subfractions. However, the contribution of some subfractions to the total curve may be 
small, or they may have comparable Km and Vmax (kcat) values. As a rule, only when 
significant differences (≥ 5-fold) exist between the Km and Vmax values for different Ab 
subfractions it is possible to determine these parameters characterizing individual 
subfractions of polyclonal Abz from the aggregated initial rate curves. 
First, we have measured the Km and Vmax values in the reaction of IN hydrolysis using two 
individual preparations of pIgGs and pIgMs not fractionated on IN-Sepharose. The initial 
rate data obtained for these Abs at the increasing IN concentration were inconsistent with 
the Michaelis-Menten kinetics and the dependences corresponded to at least three or four 
hyperbolic curves with several segments reflecting different Km values, which were 
approximately in the ranges of 5-10, 15-20, 30-50, and higher than 70-100 M (Fig. 9). Similar 
situation was observed for the mixtures of equal amounts of electrophoretically 
homogeneous IgGs (pIgGmix) and IgMs (pIgMmix) from the sera of five AIDs patients.  
For more detailed analysis of Km and kcat values characterizing different Ab fractions within 
total pool of Abzs (pIgGmix and pIgMmix) we have analyzed several individual pIgGmix and 
pIgMmix fractions eluted from IN-Sepharose (Fig. 8). First, we have measured the Km and Vmax 
values in the reaction catalyzed by IgGmix (IgGload) and IgMmix (IgMload) corresponding to the 
second fraction eluted under loading of Abs on IN-Sepharose (Fig. 8). The dependencies of 
V/[S] (hyperbolic curves; Fig. 10A) and 1/V vs 1/[S] (Fig. 10B) demonstrated virtually normal 
Michaelis-Menten character for second fractions of pIgGs and pIgMs. The Km and kcat for 
IgGload (156± 40 M; 0.3±0.1 min-1) and IgMload (130± 30 M; 2.0±0.4 min-1) were determined. 
The V/[S] and 1/V vs 1/[S] dependences for individual fractions of pIgGs and pIgMs eluted 
from IN-Sepharose in gradient of NaCl concentration (IgGsalt and IgMsalt) and by acidic buffer 
(IgGacid and IgMacid) had also typical Michaelis-Menten character. 
The affinity of pIgGs for IN (in terms of Km values) increased with the increase of their 
affinity to IN-Sepharose; for IgGsalt (Km = 44±4.0 M) corresponding to fraction 8 (eluted with 
the salt) and IgGacid (Km = 14±1.0 M) corresponding to fraction 24 (eluted with an acidic 
buffer) the affinity was 3.5– and 11-fold respectively higher than that for IgGload (156±40 
M). Similar situation was observed for the separated individual fractions of IgMmix (Fig. 
8B); pIgMsolid (Km =43±4.0 M; fraction 10 eluted with NaCl) and pIgMacid (Km = 12.8±1.0 M; 
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Fig. 9. The dependencies of the initial rates of IN hydrolysis upon the IN concentration in 
the reaction catalyzed by non-separated by affinity chromatography two individual pIgMs 
(A) and two pIgGs (B) from different patients in coordinates V vs [S]. IgM12, IgM32, IgG15, 
and IgG32 were used in different concentrations. Arrows show different hyperbolic 
fragments of complicated curves corresponding to the total dependencies. 
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Fig. 10. The dependencies of the initial rates of IN hydrolysis upon the IN concentration in 
the reaction catalyzed by fractions of pIgGmix and pIgMmix purified on IN-Sepharose (Fig. 8; 
fractions number 2; IgGload and IgMload) in coordinates V vs [S] (A). Determination of the Km 
for IN and Vmax values using the Lineweaver-Burk plot in the case of the same IgGload and 
IgMload (B). 
fraction 24 eluted with an acidic buffer) demonstrated 3– and 10-fold respectively higher 
affinity than that for pIgMload fraction (130± 30 M). The Km and kcat values corresponding to 
fractionated pIgGs and pIgMs agree with the relative contents and specific activities of the 
major Ab subfractions isolated by affinity chromatography (Fig. 8). On overall, the above 
data demonstrate extreme diversity of HIV IgGs and IgMs in their affinity to IN and in the 
relative kcat values (Figs 8-10).  
Affinity chromatography of DNase and RNase Abs from AI patients and animals 
(Baranovskii et al., 2001; Andrievskaya et al., 2002; Kuznetsova et al., 2007), healthy rabbits 
immunized with DNA, RNA, DNase I, DNase II, pancreatic RNase (Krasnorutskii et al. 
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2008a, 2008b, 2008c, 2008d, 2009) as well as AI Abs with proteolytic and other activities 
(Nevinsky et al, 1998; Semenov et al., 2004; Legostaeva et al., 2010) on resins bearing 
immobilized specific substrates using elution of Abs with different concentration of NaCl 
and an acidic buffer always leads to separation of Abs into many Abz subfractions with 
different affinity to immobilized substrate. In addition, the affinity of separated fractions for 
immobilized substrate increased gradually with the increase in eluting NaCl concentration, 
but the Km (and Vmax) values corresponding to each fraction eluted from affinity sorbent are 
individual for every patient analyzed. It means, that the apparent number of monoclonal 
Abzs with different catalytic properties within the polyclonal Abs pool may be significantly 
underestimated since it is impossible to separate Abzs with comparable affinities for a 
specific substrate or to distinguish monoclonal Abzs with similar kinetic parameters. Some 
minor monoclonal Abzs with a relatively high activity and even major Abzs with low 
activity may be hidden by major Abzs with high activity. As a consequence, the Km (and 
Vmax) values determined using Abzs not fractionated on affinity sorbents more often 
characterize the interaction of substrates with a major fraction of Abzs with the maximal 
content and highest relative enzymatic activity at condition used. At the same time, these 
characteristic are very useful for comparisons of Abs with different substrate specificities 
and from patients with different diseases. For example, it was shown that affinity of specific 
major fractions of AIDS IgGs non-fractionated on affinity resins to HSA (Km = (1.8 ± 0.6)×10-8 
M, kcat = (3.6± 1.1)×10-5 min-1) is 270-290-fold higher than to HIV RT (Km = (4.9 ± 0.5)×10-6 M, 
kcat = (2.2± 0.2)×10-3 min-1) and to -casein (Km = (5.3 ± 0.5)·10-6 M, kcat = (2.0± 0.2)×10-2 min-1) 
(Odintsova et al., 2006). At the same time, the relative rate of -casein hydrolysis was 9- and 
550-fold higher than that for HIV RT and HSA, respectively. The Km for casein ((7.3±1.2)×10-6 
M; kcat = 0.75±0.05 min-1) estimated in the reaction catalyzed by polyclonal sIgAs from 
human milk (Odintsova et al., 2005) is comparable with that for IgGs from AIDS patients, 
while the kcat is ~38-fold higher. This difference is most likely due to a higher content of anti-
casein proteolytic Abzs in human milk in comparison with blood of AIDS patients. 
The affinity of AIDS pIgGs hydrolyzing HIV RT, human casein, and HSA (Km = 0.018 – 5.3 
M; see above) as well as IN-Sepharose-purified AIDS pIgGs and pIgMs for IN (Km = 12.8-
156 M) in terms of Km values is comparable with typical affinities (Km = 0.038–7.3 M) (Paul 
et al., 1989; Kalaga et al., 1995; Legostaeva et al., 2010; Nevinsky et al., 2005, 2010a, 2010b) of 
Abzs hydrolyzing different proteins.  
The Km (and kcat) values for plasmid scDNA in the reaction catalyzed by two individual non-
fractionated AIDS IgG preparations were determined (Odintsova et al., 2006a). In the case of 
one of two preparations analyzed, the initial rate of DNA hydrolysis increases with increase 
in DNA concentration according to the Michaelis–Menten kinetics and only one pair of Km 
(53 ± 9 nM) and kcat ((2.1 ± 0.1)×10-2 min-1) was observed. For the second pIgG preparation 
two pairs of Km (2.6 ± 0.1 and 4.4 ± 0.7 nM) and kcat values ((6.7 ± 0.1)×10-2 and (29.6 ± 5.0)×10-
2 min-1) were revealed. Thus, the affinity the scDNA substrate for AIDS IgGs varied (in 
terms of Km values) in the range 2.6–53 nM, which correspond to typical Kd values for Ab–
antigen interactions and is about 3–4 orders of magnitude higher than affinity of scDNA for 
DNase I (KM = 46–58 M) (Gololobov et al., 1995). These Km values for scDNA are 
comparable with the Km for plasmid DNA (43 nM) reported previously for IgG from SLE 
patients (Gololobov et al., 1995).  
The catalysis mediated by artificial Abzs against reaction transition states is usually 
characterized by relatively low reaction rates: kcat values are 102–106-fold lower than for 
canonical enzymes (Keinan, 2005). The known kcat values for natural Abzs from AI patients 
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vary in the range of 0.001–40 min–1 (Gololobov et al., 1995; Kalaga et al., 1995; Nevinsky et 
al., 2005, 2010a, 20010b). There are only several exceptions. For example, the specific activity 
of RNase IgGs from AI patients was about 1-20% of that for RNase A and of six known 
human sera RNases, while poly(A) was hydrolyzed by Abzs 2-10-fold faster than by RNase 
A, one of the most active RNases known (Buneva et al., 1994; Baranovskii et al., 1997, 1998; 
Vlasov et al., 1998). At the same time, the specific activity of homogeneous Abzs of several 
SLE and MS patients was about 40-400% of that for RNase A (Baranovskii et al., 1998). In 
addition, the specific nucleotide-hydrolyzing activities of mouse polyclonal IgGs is 1–4 
orders of magnitude higher that those of known natural Abzs (Andryushkova et al., 2009). 
The kcat values for AIDS pIgGs hydrolyzing scDNA ((2.1-29.6)×10-2 min-1), human casein 
(2.0×10-2 min-1), HSA (3.6×10-5 min-1), and HIV RT (2.2×10-3 min-1), as well IgGs (0.3-2.9 min-
1) and IgMs (2.0-6.4 min-1) purified on IN-Sepharose (Table 2) in the IN hydrolysis were 
comparable with those for known Abzs (Odintsova et al., 2006a, 2006b; Baranova et al., 2009, 
2010). 
Currently there are no methods that can efficiently separate Abzs from catalytically inactive 
Abs against the same antigen. In addition, as it was shown above, IN-Sepharose interact not 
only with anti-IN IgMs and IgGs but bind non-specifically some other Abs. Even partial 
purification of IgGs and IgMs on IN-Sepharose (or other specific affinity resins) leads to 
significant increase in the kcat value for IN and other substrates hydrolysis. Since the specific 
activities in all cases were calculated using the total concentration of purified pIgGs and 
pIgMs and affinity chromatography on IN-Sepharose (and other affinity sorbents) cannot 
separate catalytically active and inactive anti-IN Abs, the specific IN-hydrolyzing activities 
of the individual monoclonal subfractions in the pIgG and pIgM pools may be higher than 
those of non-fractionated or partially fractionated Abs. It should be mentioned that specific 
activities of some Abzs are often significantly lower than those for canonical enzymes with 
the same catalytic activities. However, it is impossible to dismiss the RAs of Abs from 
patients with AI and viral infection as biologically inessential since they are comparable 
with those for many canonical and very important enzymes, for example, restriction 
endonucleases and repair enzymes (Gololobov et al., 1995; Nevinsky et al., 2005, 2010, 2010). 
Thus, IN-hydrolyzing IgGs and IgMs from HIV-infected patients are very heterogeneous in 
their affinity to IN-Sepharose, demonstrate different Km and Vmax values and different 
subfractions of Abzs can hydrolyze various substrates at pH from 3 to 10. In addition, in 
contrast to other Abzs with proteolytic activity they can possess for different types of 
proteolytic activities: thiol-, metal-dependent, serine- and acidic-like. 
6. Peculiarities of protein hydrolysis by AIDS abzymes and canonical 
proteases 
6.1 Casein hydrolysis by AIDS abzymes  
Casein hydrolyzing Abzs was found not only in the sera of HIV-infected patients (Odintsova 
et al., 2006b) but also in the milk of lactating women (Odintsova et al., 2005; 2011). At the first 
glance, no obvious immunizing factors could be found in clinically healthy pregnant and 
lactating women. However, pregnancy could “activate” or “trigger” autoimmune-like 
manifestations in clinically healthy women, and a sharp exacerbation of AI reactions can occur 
in some cases soon after childbirth (Amino et al., 1982; Freeman et al., 1986). Postnatal AI 
pathologies arise sometimes, including SLE, Hashimoto’s thyroiditis, phospholipids 
syndrome, polymyositis, AI myocarditis, etc. (Amino et al., 1982; Freeman et al., 1986). 
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Fig. 11. SDS-PAGE analysis of products of [32P]casein hydrolysis by human milk sIgA and 
different proteases (A) or AIDS IgGs (B) (autoradiograph). A, Lanes 1, 2, and 3 correspond 
to [32P]-casein incubated with sIgAs for 20, 40, and 60 min, respectively; lanes 4 and 5, 
incubation with trypsin for 10 and 15 min; lanes 6 and 7, incubation with proteinase K for 10 
and 15 min; lane 8, incubation with chymotrypsin for 10 min; 9, casein incubated alone for 
60 min. The reaction mixture (10 l) for analysis of proteolytic activity of different proteases 
contained 6.2 g/ml casein and sIgAs or enzymes at the following concentrations: 0.32 
g/ml trypsin, 0.064 g/ml chymotrypsin, 0.1 g/ml proteinase K, and 20 g/ml sIgA. B, 
[32P]casein was incubated for 14 h in the absence of Abs (lane 1) and in the presence IgGs 
from the sera of different AIDS patients: lane 2, IgG-1 (14 h), lanes 3 and 4, IgG2 (7 and 14 h, 
respectively), lane 5, IgG-3 (14 h). 
Parenteral or oral administration of various proteins to animals late in pregnancy leads to 
the production of the corresponding Abs at high levels (Fey et al., 1973; Mestecky et al., 
1987). Thus, pregnant women may be effectively immunized by contacts with compounds of 
viruses and bacteria that are not immunogenic in other healthy humans. There may be also 
some degree of autoimmunization during pregnancy similar to that in AI patients 
(Nevinsky et al., 2005, 2010a, 2010b and refs therein). 
It was shown that lactation is associated with the appearance of sIgA and IgG abzymes with 
DNase, RNase (Kanyshkova et al., 1997; Nevinsky et al., 2000a, 2000b), ATPase (Semenov et 
al., 2004), amylolytic (Savel'ev et al., 2001), protein- (Nevinsky et al., 1998), lipid- (Gorbunov 
et al., 2005) and polysaccharide (Karataeva et al., 2006a, 2006b) kinase activities in human 
milk. The specific activities of milk Abzs are significantly higher than those of Abzs from the 
blood of healthy lactating women and patients with different AI pathologies (Nevinsky et 
al., 2003, 2005, 2010a, 2010b and refs therein). 
We have compared the hydrolysis of -casein by canonical proteases, human milk sIgA (Fig. 
11A) and three different individual AIDS IgGs (Fig. 11B) (Odintsova et al., 2006b; 2011). The 
patterns of -casein hydrolysis by milk sIgA, AIDS IgG, trypsin, chymotrypsin, and 
proteinase K were quite different. In addition, there was observed remarkable difference in 
the hydrolysis of -casein by three individual AIDS IgG-1, IgG-2, and IgG-3 (Fig 11B).  
It should be mentioned that AIDS IgGs demonstrated only serine-like protease activity 
(Odintsova et al., 2006b), while milk IgAs additionally possess Me-dependent activity 
(Odintsova et al., 2011). Thus, possible ways of the production of Abzs with casein-
hydrolyzing activity in healthy human mothers and in AIDS patients may be different.  
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6.2 Integrase hydrolysis by AIDS abzymes  
6.2.1 Specific regularities of integrase interaction with DNA 
HIV-1 integrase catalyzes insertion of a DNA copy of the viral genome into the host genome 
(Asante-Appiah & Skalka, 1999). Therefore IN, together with RT and protease, is the main 
important target of anti-HIV drugs.  
Specific interactions between HIV IN and long terminal repeats are required for insertion of 
viral DNA into the host genome. The use of a method based on stepwise increase in ligand 
complexity allowed an estimation of the relative contributions of each nucleotide from 
oligonucleotides (ODNs) to the total affinity for IN (Bugreev et al., 2003). It was shown that 
IN interacts with ODNs through superposition of weak contacts with their bases and, more 
importantly, with the internucleotide phosphate groups. Formation of the IN complex with 
specific DNA cannot by itself account for the major contribution of enzyme specificity, 
which lies in the kcat term; the rate of 3’-processin reaction is increased by more than 5 orders 
of magnitude upon transition from non-specific to specific oligonucleotides (Bugreev et al., 
2003).  
In solution, HIV-1 IN exists in a dynamic equilibrium of monomers, dimers, tetramers and 
high-order oligomers (Deprez et al., 2000). We have recently analyzed the activity of 
different purified oligomeric forms of recombinant IN obtained after stabilization by 
platinum crosslinking and shown that these forms do not share the same in vitro catalytic 
properties (Faure et al., 2005). While monomers were inactive for all specific IN activities, 
dimers were able to catalyze the 3’-processing and the insertion of only one LTR into a short 
target DNA. In contrast, a tetramer of IN catalyzed the full-site integration of the two viral 
LTR ends into a target DNA.  
To characterize the influence of the determinants of DNA substrate specificity on the 
oligomerization status of IN, the small-angle X-ray scattering technique was used (Baranova 
et al., 2007). Under special conditions in the absence of ODNs IN existed only as monomers. 
IN preincubation with specific ODNs led mainly to formation of dimers, the relative amount 
of which correlated well with the increase in the enzyme activity. Under these conditions, 
tetramers were scarce. Nonspecific ODNs stimulated formation of catalytically inactive 
dimers and tetramers. Complexes of monomeric, dimeric and tetrameric forms of IN with 
specific and nonspecific ODNs had varying radii of gyration (Rg), suggesting that the 
specific sequence-dependent formation of IN tetramers occurs by dimerization of two 
dimers of different structure. From the data it was concluded that the DNA-induced 
oligomerization of HIV-1 IN is of extreme importance to provide substrate specificity and to 
increase the enzyme activity (Baranova et al., 2007).  
6.2.2 Effect of DNA on the integrase hydrolysis by different proteases 
It is known that a formation of multiple contacts between the same or various subunits of 
oligomeric enzymes is usually provided by multiple hydrophobic and electrostatic contacts 
and hydrogen bonds. A similar situation was observed for the dimeric forms of HIV-1 IN by 
X-ray crystallography (for review see Wlodawer 1999; Chiu & Davies, 2004 ). Analysis of 
effects of specific and nonspecific ODNs on the rate of IN proteolysis by chymotrypsin, 
trypsin, and proteinase K can provide useful information concerning a possible decrease in 
the accessibility of aromatic and positively charged amino acid residues after an enzyme 
binds its substrates, changes its conformation, or forms contacts between its subunits. It was 
interesting to compare the effect of different ODNs on the cleavage of IN by Abzs and 
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canonical proteases. The specific single-stranded (ss) 5’-GTGTGGAAAATCTCTAGCA (19-
CA), ss 5’-GTGTGGAAAATCTCTAGCAGT (21-GT), ss 5’-ACTGCTAGAGATTTTCCACAC 
(21-COM, complementary to 21-GT and to 19-CA), double-stranded (ds) 21-GT (21-GT21-
COM) and ds 19-CA (19-CA21-COM) corresponding to terminal repeats of viral DNA 
were used. 
While nonspecific d(pT)n markedly decreased the IgG-dependent hydrolysis of IN, d(pA)n 
and d(pA)nd(pT)n demonstrated no detectable protective effect (Fig. 12) (Odintsova E., 
Baranova S., and Nevinsky G.A., personal communication).  
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Fig. 12. SDS-PAGE analysis of HIV IN hydrolysis by IgGs and canonical proteases. 
Polyclonal IgGs from HIV-infected patients (A), chymotrypsin (B), trypsin (C), and 
proteinase K (D) were used for hydrolysis of IN after its preincubation in the absence and in 
the presence of various ODNs leading to the formation of different IN oligomeric forms. IN 
was pre-incubated for 1 h at 30°C in the absence (lane 7) or in the presence of saturating 
concentrations (0.2–1 mM) of ss d(pA)24 (lane 1), ss d(pT)24 (lane 2), ds d(pA)24d(pT)24 
(lane 3), ss 21-COM (lane 4), ss 21-GT (lane 5), ds 21-GT21-COM (lane 6). Then, pre-
incubated mixture was diluted 3-fold and one of three canonical proteases or pIgGs from 
HIV-infected patients was added. After 5–10 min incubation in the presence of trypsin 
(19 M), chymotrypsin (1.6 M), proteinase K (19 M) and 6 h in the presence of pIgGs 
(0.17 M) the reaction was stopped and the efficiency of IN hydrolysis was analysed by 
SDS-PAGE.  
The best protection from the hydrolysis by IgGs was observed for ss and especially ds 
specific ODNs (Fig. 12). Overall, the protective effects of all specific and nonspecific ss and 
ds ODNs from hydrolysis of IN by chymotrypsin were comparable. Therefore, one can 
suggest that the formation of IN complex with specific and nonspecific ODNs led to a 
similar decrease in the accessibility of aromatic amino acid residues as a result of their 
shielding by ODNs and/or involvement of these residues to the formation of multiple 
contacts at the interfaces of IN oligomer subunits. In contrast to chymotrypsin, nonspecific 
ODNs strongly protects IN from hydrolysis by trypsin, which cleaves peptide chains mainly 
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at the carboxyl side of lysine and arginine residues (Fig. 12). Thus, these ODNs most 
probably stimulate formation of dimeric forms of IN with more Lys- and Arg-dependent 
electrostatic contacts between the monomers. A weak protective effect of specific and 
nonspecific ODNs was observed in the case of proteinase K, which is mostly sequence-
independent. Thus, specific and nonspecific DNAs stimulate the formation of different IN 
oligomeric forms, in which aromatic and charged amino acid residues in different extent 
accessible for Abzs, chymotrypsin, and trypsin. The findings correlate with the results 
obtained by small-angle X-ray scattering, which show that all nonspecific and specific ODNs 
stimulate different changes in the structure of IN monomers and dimers free of DNA 
(Baranova et al., 2007). 
MALDI-TOF analysis of the fragments formed after IN incubation with pIgG and pIgM 
purified on IN-Sepharose was carried out (Odintsova E., Baranova S., and Nevinsky G.A., 
personal communication). The cross-sections of longitudinal slices of the gel corresponding 
to the products with approximate mol. masses 29 ± 2 (P1), 22 ± 2 (P2), 16 ± 2 (P3), and 12 ± 2 
(P4), as well as 30± 2 (P0) kDa were cut out as shown on Fig. 13 and the proteins were eluted 
from the gel. MALDI-TOF analysis has shown that P1–P4 fractions contain from four to 
eight major fragments with different molecular masses. The peptides found in the P1–P4 
fractions were digested with trypsin under standard conditions for MALDI analysis, and the 
hydrolyzates were studied. 
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Fig. 13. SDS-PAGE analysis of IN hydrolysis by pIgG-1 (lane 3, A), IgG-6 (lane 2, B), pIgM-2 
(lane 4, A) and pIgM-6 (lane 3, B) purified on IN-Sepharose after 9 h (A) and 2 h (B) of 
incubation in a nonreducing 12% gel followed by silver staining. Lanes 1 (B) and 2 (A), IN 
incubated in the absence of Abs. Lane 1 (A) protein molecular mass markers. Gel zones P1, 
P2, P3, and P4 (A) as well as P0 (B) were used for MALDI-TOF analysis (see the text). 
Seven antigenic determinants (AGDs) have been reported for HIV IN corresponding to 
amino acid residues 5–22 (AGD1), 14–35 (AGD2) (Yi et al., 2000), 58–141 (AGD3), 141–172 
(AGD4), 248–264 (AGD5) (Bizub-Bender et al., 1994), 208–228 (AGD6), and 251–271(AGD7) 
(Nilsen et al., 1996) (underlined in Fig. 14). Interestingly, 6–7 cleavage sites found by MALDI 
corresponded to the N-terminal stretch of residues 11–35, belonging to two overlapping 
antigenic determinants AGD1 and AGD2 (Fig. 14). Three clusters of cleavage sites were 
located within the long AGD3. A block of 12 closely spaced cleavage sites corresponded to 
the N-terminal part of AGD4. Only one cleavage site was located within AGD5 and four 
sites corresponded to AGD6 and AGD7. At the same time, some sites of IN cleavage, most 
notably a cluster of 16 sites between residues 175 and 202, did not corresponds to any IN 
AGD known at this moment.  
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Fig. 14. All trypsin-independent points of IN cleavage determined from the MALDI-TOF 
analysis directly mol. masses of the P0–P4 fractions and after their cleavage by trypsin. 
Numbers next to the arrows show the position of the residue within the IN sequence; 
numbers under short arrows and in parentheses correspond to the frequency of these 
cleavage sites found using different approaches. Seven known antigenic determinants of IN 
are underlined in the figure. 
Interestingly, a similar situation was observed for MS IgGs specifically hydrolyzing MBP; in 
addition to the sites of cleavage within four known AGDs of MBP, several sites were outside 
these determinants (Ponomarenko et al., 2006). Thus, the number of structurally different 
antigenic determinants in the case of IN may be great.  
Interestingly, in contrast to the absence of hydrolysis of non-specific globular proteins by 
anti-IN Abs, they first cleave IN with the accumulation of long fragments corresponding 
mainly to known AGDs and then are capable of further degradation of these long 
intermediates, and the formation of very short products was observed after 72–100 h of IN 
incubation In with Abzs (Odintsova E., Baranova S., and Nevinsky G.A., personal 
communication). AIDS anti-IN pIgGs and IgMs hydrolyze specific 20-25-mer oligopeptides 
corresponding to the IN AGDs ~30–70-fold faster than nonspecific long 20-25-mer 
oligopeptides corresponding to AGDs of human myelin basic protein and HIV RT. In 
addition, AIDS anti-IN Abzs can hydrolyze very short 3-4-mer nonspecific oligopeptides 
100–300-fold more slowly than specific ones. Therefore, the recognition and digestion of 
globular proteins and relatively short oligopeptides by the Abzs proceeds in different ways. 
Since catalytic centers of Abzs specifically hydrolyzing different proteins including IN are 
usually located on the light chains of Abs (Nevinsky et al., 2005, 2010a, 2010b, and refs 
therein), the observed hydrolysis of short oligopeptides can be a consequence of their 
interaction with light or heavy chains without significant contacts with alternative chains. 
Interestingly, separated light chains of pIgGs, pIgMs, and pIgAs from the sera of patients 
with different AI and viral diseases usually significantly more active than intact Abs in the 
hydrolysis of DNA, RNA, oligosaccharides, and proteins (Nevinsky et al., 2005, 2010a, 2010b, 
and refs therein). This phenomenon may be a consequence of a higher affinity of intact Abs, 
as compared with separated light chains, for different substrates due to interaction of the 
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substrates with both light and heavy chains of Abzs. The separation of the light chains can 
lead to a decrease in the lifetime of the existence of the complex and, as a consequence, to an 
increase in the turnover number and Vmax (kcat) of the reaction catalyzed by L-chains. Taken 
together, the absence or very weak interaction of short substrates with heavy chains of AIDS 
Abzs in contrast with globular molecules proteins (and higher rate of the reaction) may be a 
main reason of a decrease of specificity of Abzs action in the case of short oligopeptides; one 
cannot exclude that light (or heavy) chains of some Abzs can effectively hydrolyzed short 
oligopeptides of any sequences.  
We have shown that in vitro IgGs and IgMs hydrolyzing IN significantly decrease the 3’-
processing and integration reaction catalyzed by IN (for example, Fig. 15) (Odintsova E., 
Baranova S., and Nevinsky G.A., personal communication).  
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Fig. 15. Effect of IN-hydrolyzing IgGs and IgMs from AIDS patients on the rate of the 3’-
processing reaction.  
7. Conclusion  
According to modern point of view, the immune response to the viral components is the 
most important factor providing slow transition of HIV infection to the stage of AIDS (Fauci 
et al., 2008). Since AIDS anti-IN anti-RT Abs can efficiently hydrolyze IN and RT (Odintsova 
et al., 2006b; Baranova et al., 2009, 2010), a positive role of abzymes in counteracting the 
infection cannot be excluded and these polyclonal and corresponding monoclonal Abzs with 
proteolytic activities are potentially interesting for designing new anti-HIV agents. In 
addition, detection of IN-hydrolyzing activity can be useful for diagnostic purposes and for 
assessment of the immune status in AIDS patients. 
The field of monoclonal Abzs with immunotherapeutic potential has recently been reviewed 
(see “Introduction”). Abzs that cleave HIV envelope gp120 protein may find their use in the 
treatment of AIDS (Tellier, 2002; Stockwin & Holmes, 2003). pIgG degrading gp120 was also 
obtained taking advantage of the susceptibility of SJL mice to a peptide-induced AI 
disorder, experimental AI encephalomyelitis (Ponomarenko et al., 2006). Immunization of 
specific pathogen-free SJL mice with structural fragments of gp120 fused in-frame with the 
encephalitogenic MBP(85-101) peptide resulted in a pronounced disease-associated immune 
response against these antigens. This strategy can be generalized to create catalytic vaccines 
against viral pathogens (Ponomarenko et al., 2006). In addition, Abzs with different catalytic 
activities can be used for different purposes (see “Introduction”).  
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In conclusion, a number of studies of Abzs show the extremely wide potential of the 
immune system in producing Abzs possessing very different enzymatic activities, which 
very often are not comparable with those of known enzymes, and natural Abs with specified 
and novel functions may have wide potential for biotechnology and medicine. 
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9. Abbreviations 
Abs - antibodies 
Abzs - abzymes - or catalytically active antibodies 
AG - antigen 
AI - autoimmune 
AD - autoimmune disease 
AIDS - human autoimmune deficit syndrome 
BSA - bovine serum albumin 
CC - correlation coefficient 
HSCs - hematopoietic stem cells 
sc - supercoiled 
ss and ds - single- and double-stranded - respectively 
CBA - (CBAxC57BL)F1 mice 
HT - Hashimoto’s thyroiditis 
hMBP - human myelin basic protein 
MFT - microsomal fraction of thyrocytes 
MBP - myelin basic protein 
MS - multiple sclerosis 
nat-DNA and den-DNA - native and denatured DNA - respectively 
MHO - maltoheptaose 
pAbs and pIgGs - polyclonal Abs and IgGs - respectively 
RF - rheumatoid factor 
SLE- systemic lupus erythematosus - SDS-PAGE - SDS-polyacrylamide gel electrophoresis 
TBE - tick-borne encephalitis 
VIP - vasoactive intestinal peptide 
RA - relative activity 
CFU-GM - granulocytic-macrophagic colony-forming unit 
BFU-E - erythroid burst-forming unit 
CFU-GEMM - granulocytic-erythroid-megakaryocytic- macrophagic colony-forming unit 
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